Charlotte Videbaek
Director/Miembro de la Junta en CESSATECH A/S .
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Adam Sinding Steensberg | M | 50 | 4 años | |
| Martin Olin | M | 55 | 4 años | |
| Flemming Steen Jensen | M | 63 | 4 años | |
| Peter Birk | M | 59 | 4 años | |
| Jes Trygved | M | 51 | 8 años | |
| Rachel Curtis Gravesen | F | 55 | 2 años | |
| Steen Henneberg | M | 75 | 4 años | |
| Louise Bak | F | - | 3 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Ulla Hald Buhl | F | 60 | 1 años | |
| Jakob W. Gotfredsen | M | - |
Neurokey A/S
 Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | 3 años |
| Uno Jakob Weber | M | - |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | 3 años |
| Christian Torp-Pedersen | M | - |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | 3 años |
| Lars Kober | M | - |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | 3 años |
| Benedikte Bandak | F | - | - | |
| Jens Peter Balling | M | - | - | |
| Anders Götzsche | M | 56 | 15 años | |
| Iman Barilero | M | - | - | |
| Jørgen Okkels Nielsen | M | 76 | 5 años | |
| Marie-Laure Jeanne Antoinette Pochon | F | 65 | 5 años | |
| Kristian Sibilitz | M | - | - | |
| Christoffer Erik Lorenzen | M | 48 | 5 años | |
| Tugba Ceylan | F | - | 1 años | |
| Bettina Nygaard Nielsen | M | 47 | - | |
| Inge Holm Lauritzen | F | 57 | 9 años | |
| Etienne Adriansen | M | 60 | - | |
| Per Wold-Olsen | M | 76 | 4 años | |
| Klaus Bæk Simonsen | M | - | - | |
| Finn Eggert Sørensen | M | 70 |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | - |
| Egil Bodd | M | 69 | - | |
| Mads Buhl Axelsen | M | 66 |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | - |
| Frank Knudsen | M | 66 |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | - |
| Carsten Schou | M | - |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | - |
| Flemming Bent Lindeløv | M | 75 | - | |
| Hans Henrik Munch-Jensen | M | 64 | 8 años | |
| Peter Moldt | M | 65 |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | - |
| Peter Bisgaard | M | 50 |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | - |
| Helle Størum | F | 57 | 9 años |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Dinamarca | 37 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Charlotte Videbaek
- Red Personal